[Skip to Navigation]
Sign In
Comment & Response
August 2018

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

Author Affiliations
  • 1Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 2Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 4Department of Biostatistics, Harvard University, Boston, Massachusetts
JAMA Oncol. 2018;4(8):1135-1136. doi:10.1001/jamaoncol.2018.0881
Add or change institution